BIOAVAILABILITY OF DILTIAZEM AS A FUNCTION OF THE ADMINISTERED DOSE

被引:22
作者
BIANCHETTI, G
REGAZZI, M
RONDANELLI, R
ASCALONE, V
MORSELLI, PL
机构
[1] SYNTHELABO RECH,STUDY & RES SYNTHELABO LAB,DEPT CLIN RES,I-20090 LIMITO,ITALY
[2] SYNTHELABO RECH,ETUD & RECH SYNTHELABO LAB,DEPT CLIN RES,F-75013 PARIS,FRANCE
[3] UNIV PAVIA,POLICLIN SAN MATTEO,IST RICOVERO & CURA CARATTERE SCI,DEPT PHARMACOL,I-27100 PAVIA,ITALY
关键词
DILTIAZEM; BIOAVAILABILITY; 1ST-PASS; HEALTHY VOLUNTEERS;
D O I
10.1002/bdd.2510120508
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diltiazem undergoes extensive first-pass metabolism; extrapolation from single to repeated administration thus underestimates plasma concentration values. In order to validate the hypothesis of a partially saturable first-pass effect, four single doses of diltiazem (10, 20, 40, and 120 mg) were administered at weekly intervals to eight healthy volunteers. Results showed that: (a) the inter-subject variability was highest at the lowest dose and lowest at the highest dose; (b) bioavailability was almost nil in 3 of 8 of the subjects after the administration of the 10 mg dose; (c) the mean bioavailability increased with the dose from 11.8 +/- 2.5 per cent after 10 mg to 28.2 per cent after 120 mg; (d) the elimination half-life was dose-related; (e) the renal excretion of diltiazem increased with the administered dose from 1.0 +/- 0.3 per cent after 10 mg to 3.0 +/- 0.5 per cent after 120 mg; (f) the greatest amounts of circulating metabolites were present after the lowest doses. These results are consistent with a partially saturable first-pass effect for diltiazem.
引用
收藏
页码:391 / 401
页数:11
相关论文
共 22 条
[1]  
ANDREN L, 1988, AM J CARDIOL, V62, P114
[2]   AUTOMATED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH COLUMN SWITCHING FOR ONLINE CLEANUP AND ANALYSIS OF DILTIAZEM AND METABOLITES IN HUMAN-PLASMA [J].
ASCALONE, V ;
FLAMINIO, L .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 495 :358-360
[3]  
ASCALONE V, 1987, J CHROMATOGR-BIOMED, V42, P239
[4]   DILTIAZEM - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY [J].
CHAFFMAN, M ;
BROGDEN, RN .
DRUGS, 1985, 29 (05) :387-454
[5]  
DUBRUC C, 1985, 2ND EUR C BIOPH PHAR
[6]  
GIBALDI M, 1975, PHARMACOKINETICS, P232
[8]   PHARMACOKINETICS OF DILTIAZEM AFTER INTRAVENOUS AND ORAL-ADMINISTRATION [J].
HERMANN, P ;
RODGER, SD ;
REMONES, G ;
THENOT, JP ;
LONDON, DR ;
MORSELLI, PL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (03) :349-352
[9]  
HERMANN P, 1985, ACTA PHARMACOL TOX, V57, P10
[10]  
HOGLUND P, 1989, THER DRUG MONIT, V11, P543